Уреаплазма уреалитикум (U. urealyticum), IgM

Ureaplasma urealyticum IgA antibody testing assesses humoral immune response to U. urealyticum and supports the evaluation of urethritis where multiple pathogens are plausible. Anti–Ureaplasma urealyticum IgA can help identify recent or ongoing exposure and contributes adjunctive evidence when determining the infectious etiology alongside nucleic acid tests, culture data, and clinical examination. This assay is used to investigate possible latent or subclinical ureaplasma infection and to contextualize symptoms compatible with urethritis. Serial measurement may assist in monitoring response when antimicrobial therapy is directed against U. urealyticum, recognizing that serology alone does not establish causality.

Ureaplasma urealyticum belongs to the mycoplasma group, a lineage of very small, cell wall–deficient bacteria regarded among the smallest free‑living organisms. Clinical attention centers on U. urealyticum and U. parvum, which may cause disease yet frequently colonize the urogenital tract without symptoms. Colonization is common among sexually active women (approximately 40%–70%) and occurs less often in men; transmission is sexual or perinatal. U. urealyticum is one of several possible causes of urethritis. Other pathogens include Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, and Mycoplasma genitalium. Because signs and symptoms overlap, laboratory testing is required to define the etiologic agent and guide therapy. Manifestations of urethritis may include dysuria and urethral discomfort, mucous urethral discharge or pyuria in men, and vaginal discharge, dysuria, or lower abdominal pain in women. The relationship between ureaplasma colonization and adverse pregnancy outcomes remains uncertain. Some investigators have proposed associations with preterm delivery, stillbirth, infertility, and chorioamnionitis, and with neonatal meningitis, bronchopulmonary dysplasia, or pneumonia; these links are unproven. Routine testing during pregnancy is therefore not mandated, although some laboratories advocate detection and treatment even in asymptomatic individuals. Following exposure to foreign antigens, the host mounts an antibody response that includes IgG, IgM, and IgA. IgA exists in serum and as secretory IgA in mucosal fluids; the secretory form has antibacterial activity, whereas the precise role of serum IgA is less clearly defined. Selective IgA deficiency is associated with autoimmune and allergic conditions. In ureaplasma infection, IgA (and IgG) typically becomes detectable no earlier than one week after acquisition, may rise more rapidly and to higher levels with reinfection, and generally declines over months after effective eradication. Because colonization does not always equate to disease, anti–U. urealyticum IgA serves as supportive evidence rather than a stand‑alone diagnostic criterion.